トロンビン市場：タイプ、形態、エンドユーザー別-2025-2030年の世界予測

トロンビン市場は、2023年に6億4,896万米ドルと評価され、2024年には6億8,505万米ドルに達すると予測され、CAGR 6.14%で成長し、2030年には9億8,529万米ドルに達すると予測されています。

血液凝固に重要な酵素であるトロンビンは、止血を助けるために医療処置に広く利用されています。トロンビンの主な必要性は、出血をコントロールする役割に起因しており、外科的設定や創傷管理に不可欠です。トロンビンの応用範囲は、病院から専門の手術センターまで様々な最終用途に及び、バイオ医薬品研究への展開が新たな一面を加えています。トロンビンの市場は、世界の外科手術の増加、心血管疾患の有病率の上昇、トロンビンの有効性を高めるバイオテクノロジーの進歩などの成長要因の影響を受けています。組換え型トロンビンやその他の生物工学的改良型の開発に新たな機会があり、従来の型に関連するアレルゲンや病原体トランスミッションの課題に対処することが期待されています。

しかし、市場は限界に直面しており、特に製造コストの高さや代替凝固剤との競合が挙げられます。規制上のハードルや厳しい安全性要件も大きな課題となっており、製品承認や市場拡大を遅らせる可能性があります。また、一部の患者における副作用の懸念もあり、より広範な適用が制限される可能性があります。このような課題にもかかわらず、トロンビンのバイオアベイラビリティと特異性を高めるための分子改変に焦点を当てることで、技術革新が事業の成長を促進することができます。さらに、保存期間が長く、安定した製剤のトロンビンアナログを開発する研究により、新たな市場を開拓できる可能性があります。

トロンビン市場のダイナミックな性質は、成熟したアプリケーションと新しい技術的進歩の融合を反映しています。組換えDNA技術は、より安全で制御されたトロンビン変種を提供し、事業発展の有望な分野です。市場機会を生かすために、企業はバイオテクノロジー企業や研究機関との戦略的パートナーシップに投資し、規制基準に沿った共同イノベーションを推進すべきです。このようなニュアンスを理解することにより、企業は市場情勢をより良くナビゲートすることができ、革新的な調査と戦略的な先見性を組み合わせることにより、課題を効果的に軽減しながら、その大きな可能性を引き出すことができます。

市場力学：急速に進化するトロンビン市場の主要市場インサイトを公開

トロンビン市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 外科手術件数の増加と止血剤の必要性
  • 食肉の結着剤としてのトロンビンの利用拡大
• 市場抑制要因
  • トロンビンの複雑な製造工程
• 市場機会
  • トロンビンの使用を促進する医薬品開発活動の拡大
  • トロンビンの機能性の進歩
• 市場の課題
  • トロンビンの過剰使用による主な健康リスク

ポーターの5つの力：トロンビン市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、トロンビン市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：トロンビン市場における外部からの影響の把握

外部マクロ環境要因は、トロンビン市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析トロンビン市場における競合情勢の把握

トロンビン市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックストロンビン市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、トロンビン市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨トロンビン市場における成功への道筋を描く

トロンビン市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 外科手術の増加と止血剤の必要性
    • 肉類の結合剤としてのトロンビンの利用拡大
  • 抑制要因
    • トロンビンの複雑な制作プロセス
  • 機会
    • トロンビンの使用を促進する医薬品開発活動の拡大
    • トロンビンの機能の進化
  • 課題
    • トロンビンの過剰使用に関連する重大な健康リスク
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 トロンビン市場：タイプ別

• 牛トロンビン
• ヒト血漿トロンビン
• 組み換えトロンビン

第7章 トロンビン市場：形態別

• 液体
• 粉

第8章 トロンビン市場：エンドユーザー別

• 病院・クリニック
• 医療調査・学術機関

第9章 南北アメリカのトロンビン市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のトロンビン市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのトロンビン市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Baxter International Inc.
• Bayer AG
• BIOFAC A/S
• BioMedica Diagnostics Inc.
• BioPharm Laboratories, LLC
• Cayman Chemical
• DiaPharma Group, Inc.
• Grifols, S.A.
• Johnson & Johnson Services, Inc.
• Medix Biochemica USA Inc.
• Merck KGaA
• Mochida Pharmaceutical Co., Ltd.
• MyBioSource
• Octapharma AG
• Pfizer, Inc.
• Prolytix
• Prospec-Tany Technogene Ltd.
• Proteintech Group, Inc.
• Regen Lab SA
• Rocky Mountain Biologicals, LLC.
• Shanghai RAAS blood products co., Ltd
• Takeda Pharmaceutical Company Limited.
• Teleflex Incorporated.
• Thermo Fisher Scientific Inc.
• XD BIOCHEMS LIMITED

LIST OF FIGURES

• FIGURE 1. THROMBIN MARKET RESEARCH PROCESS
• FIGURE 2. THROMBIN MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL THROMBIN MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL THROMBIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL THROMBIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL THROMBIN MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL THROMBIN MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL THROMBIN MARKET SIZE, BY FORM, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL THROMBIN MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL THROMBIN MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL THROMBIN MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS THROMBIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS THROMBIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES THROMBIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES THROMBIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC THROMBIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC THROMBIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA THROMBIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA THROMBIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. THROMBIN MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. THROMBIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. THROMBIN MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL THROMBIN MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL THROMBIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL THROMBIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. THROMBIN MARKET DYNAMICS
• TABLE 7. GLOBAL THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL THROMBIN MARKET SIZE, BY BOVINE THROMBIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL THROMBIN MARKET SIZE, BY HUMAN PLASMA THROMBIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL THROMBIN MARKET SIZE, BY RECOMBINANT THROMBIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL THROMBIN MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL THROMBIN MARKET SIZE, BY POWDER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL THROMBIN MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL THROMBIN MARKET SIZE, BY MEDICAL RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS THROMBIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 21. ARGENTINA THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 24. BRAZIL THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 27. CANADA THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 28. CANADA THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 29. CANADA THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 30. MEXICO THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. UNITED STATES THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES THROMBIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 37. ASIA-PACIFIC THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC THROMBIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 41. AUSTRALIA THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 44. CHINA THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. CHINA THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 46. CHINA THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. INDIA THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. INDIA THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 49. INDIA THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. INDONESIA THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. JAPAN THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. MALAYSIA THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. PHILIPPINES THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 62. SINGAPORE THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. SOUTH KOREA THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. TAIWAN THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. THAILAND THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 74. VIETNAM THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. EUROPE, MIDDLE EAST & AFRICA THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA THROMBIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 81. DENMARK THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. EGYPT THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. FINLAND THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. FRANCE THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. GERMANY THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. ISRAEL THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. ITALY THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. ITALY THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 101. ITALY THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 102. NETHERLANDS THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. NIGERIA THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. NORWAY THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. POLAND THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. POLAND THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 113. POLAND THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. QATAR THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. QATAR THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 116. QATAR THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. RUSSIA THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. SAUDI ARABIA THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. SOUTH AFRICA THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. SPAIN THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. SWEDEN THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. SWITZERLAND THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 135. TURKEY THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. UNITED ARAB EMIRATES THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. UNITED KINGDOM THROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM THROMBIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM THROMBIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. THROMBIN MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 145. THROMBIN MARKET, FPNV POSITIONING MATRIX, 2023

The Thrombin Market was valued at USD 648.96 million in 2023, expected to reach USD 685.05 million in 2024, and is projected to grow at a CAGR of 6.14%, to USD 985.29 million by 2030.

Thrombin, a crucial enzyme for blood coagulation, is extensively utilized in medical procedures to aid in hemostasis. Its primary necessity stems from its role in controlling bleeding, making it indispensable in surgical settings and wound management. The application scope for thrombin spans across various end-uses, from hospitals to specialized surgical centers, and its deployment in biopharmaceutical research adds another dimension. The market for thrombin is influenced by growth factors such as an increase in surgical procedures globally, the rising prevalence of cardiovascular diseases, and advancements in biotechnology that enhance thrombin's efficacy. Emerging opportunities lie in the development of recombinant thrombin and other bioengineered variants, which promise to address allergens and pathogen-transmission challenges associated with traditional forms.

However, the market faces limitations, notably the high cost of thrombin production and competition from alternative clotting agents. Regulatory hurdles and stringent safety requirements also pose significant challenges, potentially delaying product approvals and market expansion. There are also concerns about adverse reactions in a subset of patients that can limit its broader application. Despite these challenges, innovation can drive business growth by focusing on molecular modifications to enhance thrombin bioavailability and specificity. Moreover, research into developing thrombin analogs with longer shelf life and stable formulations could open new markets.

The dynamic nature of the thrombin market reflects a blend of matured applications and nascent technological advancements. Recombinant DNA technology represents a promising area for business development, providing a safer and more controlled thrombin variant. To capitalize on market opportunities, businesses should invest in strategic partnerships with biotechnology firms and research institutions, promoting collaborative innovation that aligns with regulatory standards. By understanding these nuances, businesses can better navigate the thrombin market landscape, combining innovative research with strategic foresight to tap into its vast potential while mitigating challenges effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Thrombin Market

The Thrombin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing number of surgical procedures and need for thrombin hemostatic agents
  • Expanding utilization of thrombin as a binding agent for meats
• Market Restraints
  • Complex production process of thrombin
• Market Opportunities
  • Expanding drug development activities promoting the usage of thrombin
  • Advancements in the functionalities of thrombin
• Market Challenges
  • Major health risks associated with excessive usage of thrombin

Porter's Five Forces: A Strategic Tool for Navigating the Thrombin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Thrombin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Thrombin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Thrombin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Thrombin Market

A detailed market share analysis in the Thrombin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Thrombin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Thrombin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Thrombin Market

A strategic analysis of the Thrombin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Thrombin Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Baxter International Inc., Bayer AG, BIOFAC A/S, BioMedica Diagnostics Inc., BioPharm Laboratories, LLC, Cayman Chemical, DiaPharma Group, Inc., Grifols, S.A., Johnson & Johnson Services, Inc., Medix Biochemica USA Inc., Merck KGaA, Mochida Pharmaceutical Co., Ltd., MyBioSource, Octapharma AG, Pfizer, Inc., Prolytix, Prospec-Tany Technogene Ltd., Proteintech Group, Inc., Regen Lab SA, Rocky Mountain Biologicals, LLC., Shanghai RAAS blood products co., Ltd, Takeda Pharmaceutical Company Limited., Teleflex Incorporated., Thermo Fisher Scientific Inc., and XD BIOCHEMS LIMITED.

Market Segmentation & Coverage

This research report categorizes the Thrombin Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Bovine Thrombin, Human Plasma Thrombin, and Recombinant Thrombin.
• Based on Form, market is studied across Liquid and Powder.
• Based on End-User, market is studied across Hospitals & Clinics and Medical Research & Academic Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing number of surgical procedures and need for thrombin hemostatic agents
    • 5.1.1.2. Expanding utilization of thrombin as a binding agent for meats
  • 5.1.2. Restraints
    • 5.1.2.1. Complex production process of thrombin
  • 5.1.3. Opportunities
    • 5.1.3.1. Expanding drug development activities promoting the usage of thrombin
    • 5.1.3.2. Advancements in the functionalities of thrombin
  • 5.1.4. Challenges
    • 5.1.4.1. Major health risks associated with excessive usage of thrombin
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Thrombin Market, by Type

• 6.1. Introduction
• 6.2. Bovine Thrombin
• 6.3. Human Plasma Thrombin
• 6.4. Recombinant Thrombin

7. Thrombin Market, by Form

• 7.1. Introduction
• 7.2. Liquid
• 7.3. Powder

8. Thrombin Market, by End-User

• 8.1. Introduction
• 8.2. Hospitals & Clinics
• 8.3. Medical Research & Academic Institutes

9. Americas Thrombin Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Thrombin Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Thrombin Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Baxter International Inc.
• 3. Bayer AG
• 4. BIOFAC A/S
• 5. BioMedica Diagnostics Inc.
• 6. BioPharm Laboratories, LLC
• 7. Cayman Chemical
• 8. DiaPharma Group, Inc.
• 9. Grifols, S.A.
• 10. Johnson & Johnson Services, Inc.
• 11. Medix Biochemica USA Inc.
• 12. Merck KGaA
• 13. Mochida Pharmaceutical Co., Ltd.
• 14. MyBioSource
• 15. Octapharma AG
• 16. Pfizer, Inc.
• 17. Prolytix
• 18. Prospec-Tany Technogene Ltd.
• 19. Proteintech Group, Inc.
• 20. Regen Lab SA
• 21. Rocky Mountain Biologicals, LLC.
• 22. Shanghai RAAS blood products co., Ltd
• 23. Takeda Pharmaceutical Company Limited.
• 24. Teleflex Incorporated.
• 25. Thermo Fisher Scientific Inc.
• 26. XD BIOCHEMS LIMITED